A biotech with plans to make an oral drug that has the same target as Humira, formerly the world’s top-selling medicine, has raised $47.5 million

Since Takeda paid billions for Nimbus Therapeutics’ program in 2022, TYK2 has been one of immunology’s hottest targets. But it’s also crowded, with biotechs herding

The UK government’s drug rebate tax will fall to 14.5% for new drugs next year, down from nearly 23%, according to new details following the

D3 Bio has secured $108 million in a Series B fundraise, with the main goal of advancing its lead drug candidate targeting KRAS-G12C into global

With two cancer drugs in clinical testing, BlossomHill Therapeutics has convinced investors to fuel the San Diego startup with another $84 million in its attempt